Supplementary Material for: The power of a good word: Enhancing the efficacy of analgesics in clinical settings by Treister R. (19801920)

“…In study 2, in the last two timepoints of assessment, participants in the EC arm also consumed fewer doses of opioids than participants in the RC arm (p<0.001). No significant differences were found in vital signs. Conclusions: We provide ecological evidence that positive information about treatment significantly decreases pain and opioid consumption during routine clinical care. …”

Supplementary Material for: Clinical and Experimental Insights into the Role of NETosis in IgA Nephropathy Pathogenesis by figshare admin karger (2628495)

“…Inhibiting NETosis with GSK484 reduced CitH3 levels in IgAN mice and improved clinical outcomes, including decreased proteinuria and increased serum albumin. …”

Table 2_Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.docx by Yutao Liu (87989)

“…</p>Results<p>(1) Anti-CTD Abs (+): higher proportion of female patients, increased relapse frequency; decreased red blood cell (RBC) count and aspartate aminotransferase (AST) levels. (2) ATAbs (+): greater incidence of acute brainstem syndrome (ABS); reduced peripheral leukocyte, neutrophil, and lymphocyte counts; elevated serum urea levels. (3) Double (+): marked female predominance, higher incidence of ABS, decreased RBC count, hemoglobin (Hb) levels, and cerebrospinal fluid (CSF) chloride concentration; elevated serum urea. (4) AQP4-IgG association: AQP4-IgG-positive patients were more frequently female, with higher prevalence of anti-CTD Abs positivity but lower prevalence of ATAbs positivity. (5) Prognostic analysis: both double-positive and single-antibody-positive groups showed higher disability (EDSS ≥4.0/≥6.0) compared with antibody-negative patients, although no significant differences were observed between the two single-antibody subgroups. (6) Multivariate analysis identified combined antibody positivity (OR = 16.292), baseline EDSS score (OR = 3.179), and age at onset (OR = 1.052) as independent predictors of poor clinical outcomes.…”

Table 4_Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.docx by Yutao Liu (87989)

“…</p>Results<p>(1) Anti-CTD Abs (+): higher proportion of female patients, increased relapse frequency; decreased red blood cell (RBC) count and aspartate aminotransferase (AST) levels. (2) ATAbs (+): greater incidence of acute brainstem syndrome (ABS); reduced peripheral leukocyte, neutrophil, and lymphocyte counts; elevated serum urea levels. (3) Double (+): marked female predominance, higher incidence of ABS, decreased RBC count, hemoglobin (Hb) levels, and cerebrospinal fluid (CSF) chloride concentration; elevated serum urea. (4) AQP4-IgG association: AQP4-IgG-positive patients were more frequently female, with higher prevalence of anti-CTD Abs positivity but lower prevalence of ATAbs positivity. (5) Prognostic analysis: both double-positive and single-antibody-positive groups showed higher disability (EDSS ≥4.0/≥6.0) compared with antibody-negative patients, although no significant differences were observed between the two single-antibody subgroups. (6) Multivariate analysis identified combined antibody positivity (OR = 16.292), baseline EDSS score (OR = 3.179), and age at onset (OR = 1.052) as independent predictors of poor clinical outcomes.…”

Table 1_Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.docx by Yutao Liu (87989)

“…</p>Results<p>(1) Anti-CTD Abs (+): higher proportion of female patients, increased relapse frequency; decreased red blood cell (RBC) count and aspartate aminotransferase (AST) levels. (2) ATAbs (+): greater incidence of acute brainstem syndrome (ABS); reduced peripheral leukocyte, neutrophil, and lymphocyte counts; elevated serum urea levels. (3) Double (+): marked female predominance, higher incidence of ABS, decreased RBC count, hemoglobin (Hb) levels, and cerebrospinal fluid (CSF) chloride concentration; elevated serum urea. (4) AQP4-IgG association: AQP4-IgG-positive patients were more frequently female, with higher prevalence of anti-CTD Abs positivity but lower prevalence of ATAbs positivity. (5) Prognostic analysis: both double-positive and single-antibody-positive groups showed higher disability (EDSS ≥4.0/≥6.0) compared with antibody-negative patients, although no significant differences were observed between the two single-antibody subgroups. (6) Multivariate analysis identified combined antibody positivity (OR = 16.292), baseline EDSS score (OR = 3.179), and age at onset (OR = 1.052) as independent predictors of poor clinical outcomes.…”

Table 3_Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.docx by Yutao Liu (87989)

“…</p>Results<p>(1) Anti-CTD Abs (+): higher proportion of female patients, increased relapse frequency; decreased red blood cell (RBC) count and aspartate aminotransferase (AST) levels. (2) ATAbs (+): greater incidence of acute brainstem syndrome (ABS); reduced peripheral leukocyte, neutrophil, and lymphocyte counts; elevated serum urea levels. (3) Double (+): marked female predominance, higher incidence of ABS, decreased RBC count, hemoglobin (Hb) levels, and cerebrospinal fluid (CSF) chloride concentration; elevated serum urea. (4) AQP4-IgG association: AQP4-IgG-positive patients were more frequently female, with higher prevalence of anti-CTD Abs positivity but lower prevalence of ATAbs positivity. (5) Prognostic analysis: both double-positive and single-antibody-positive groups showed higher disability (EDSS ≥4.0/≥6.0) compared with antibody-negative patients, although no significant differences were observed between the two single-antibody subgroups. (6) Multivariate analysis identified combined antibody positivity (OR = 16.292), baseline EDSS score (OR = 3.179), and age at onset (OR = 1.052) as independent predictors of poor clinical outcomes.…”

Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis by Wanying Bao (19665769)

“…However, a systematic evaluation of its clinical benefits remains elusive.</p> <p>We conducted a systematic search in several databases. …”

Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practice by Hélène Verdoux (110251)

“…After clozapine initiation, a decreased frequency of challenging behavior persisting over time was reported in most participants included in clinical studies, and a significant reduction in the number of admissions in the population-based two-year mirror-image study. …”

Supplementary file 1_Clinical features of benign paroxysmal positional vertigo in the elderly.docx by Ran Zhou (1450756)

“…This study compared the clinical characteristics, treatments, and prognoses with patients.…”

Table 1_The clinical prediction model to distinguish between colonization and infection by Klebsiella pneumoniae.xlsx by Xiaoyu Zhang (62901)

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …”